58.79
-0.03
(-0.05%)
At close: 4:00:01 PM EDT
58.79
0.00
(0.00%)
After hours: 4:20:00 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 0.96 | 1.14 | 4.9 | 6.41 |
| Low Estimate | 0.88 | 0.98 | 4.13 | 5.47 |
| High Estimate | 1.08 | 1.26 | 5.25 | 7.49 |
| Year Ago EPS | 0.79 | 0.91 | 4.23 | 4.9 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 9 | 7 |
| Avg. Estimate | 231.21M | 279.57M | 1.19B | 1.46B |
| Low Estimate | 219.1M | 264.9M | 1.15B | 1.36B |
| High Estimate | 240M | 300M | 1.22B | 1.53B |
| Year Ago Sales | 195.88M | 231.35M | 1.02B | 1.19B |
| Sales Growth (year/est) | 18.04% | 20.84% | 16.81% | 22.69% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.7 | 0.76 | 1 | 1.16 |
| EPS Actual | 0.79 | 0.91 | 1.27 | 1.26 |
| Difference | 0.09 | 0.15 | 0.27 | 0.1 |
| Surprise % | 13.57% | 20.10% | 27.05% | 8.73% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.96 | 1.14 | 4.9 | 6.41 |
| 7 Days Ago | 0.96 | 1.15 | 4.9 | 6.45 |
| 30 Days Ago | 0.95 | 1.15 | 4.93 | 6.45 |
| 60 Days Ago | 0.97 | 1.19 | 5.05 | 6.53 |
| 90 Days Ago | 0.97 | 1.16 | 5.05 | 6.22 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 3 |
| Up Last 30 Days | 1 | 1 | 2 | 3 |
| Down Last 7 Days | 2 | 2 | 1 | -- |
| Down Last 30 Days | 2 | 2 | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| HALO | 21.73% | 25.09% | 15.90% | 30.70% |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2025 |
| Reiterates | Benchmark: Buy to Buy | 2/20/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/19/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/4/2025 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 1/13/2025 |
| Maintains | Piper Sandler: Neutral to Neutral | 1/10/2025 |
Related Tickers
CPRX Catalyst Pharmaceuticals, Inc.
22.52
+1.49%
ARGX argenx SE
596.20
+1.47%
EXEL Exelixis, Inc.
36.19
+0.11%
HRMY Harmony Biosciences Holdings, Inc.
28.46
+1.86%
ADMA ADMA Biologics, Inc.
21.31
+0.38%
BMRN BioMarin Pharmaceutical Inc.
59.17
+0.60%
INCY Incyte Corporation
58.21
+0.83%
MDGL Madrigal Pharmaceuticals, Inc.
301.66
-1.99%
CORT Corcept Therapeutics Incorporated
62.24
-3.65%
FOLD Amicus Therapeutics, Inc.
6.83
+1.94%